Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib

Oncogene

Volumn 23, Issue 13, 2004, Pages 2305-2314

  Cervi, David ^a   Truong, Amandine H L ^a   Lee, Jane S ^a   Sukhai, Natasha ^a   Li, You Jun ^a   Koki, Alane ^b   Ben David, Yaacov ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b IPSOGEN   (France)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

c Kit phosphorylation; Celecoxib; Erythroleukemia; p53 status; Resistance

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ERYTHROPOIETIN RECEPTOR; PROTEIN P53; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; PHOSPHOTRANSFERASE; PYRAZOLE DERIVATIVE; STEM CELL FACTOR RECEPTOR; SULFONAMIDE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST TRANSFORMATION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; ERYTHROLEUKEMIA; ERYTHROLEUKEMIA CELL; FRIEND LEUKEMIA VIRUS; IN VITRO STUDY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANIMAL; DRUG RESISTANCE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALIA; FRIEND MURINE LEUKEMIA VIRUS; MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MICE; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRAZOLES; RECEPTORS, ERYTHROPOIETIN; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1842536850     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207400     Document Type: Article

References (32)

1. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P and Ogier-Denis E. (2002). J. Biol. Chem., 277 (31), 27613-27621.
2. Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A and Sawyer ST. (1999). Blood, 39, 3757-3773.
3. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B and Kinzler KW. (1996). Carcinogenesis, 17, 1757-1760.
4. Ben-David Y, Lavigueur A, Cheong GY and Bernstein A. (1990). The New Biologist, 2, 1015-1023.
5. Berman KS, Verma UN, Harburg G, Minna JD, Cobb MH and Gaynor RB. (2002). Clin. Cancer Res., 8, 354-360.
6. Bittorf T, Buchse T, Sasse T, Jaster R and Brock J. (2001). Cell Signal, 9, 673-681.
7. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL and Dannenberg AJ. (1999). Cancer Res., 59, 991-994.
8. DuBois RN, Giardello FM and Smalley WE. (1996). Gastroenterol. Clin. North Am., 25, 773-791.
9. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA and Conti CJ. (1999). Mol. Carcinog., 25, 231-240.
10. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR and Offerhaus GJ. (1993). N. Eng. J. Med., 328, 1313-1316.
11. Harris RE, Alshafie GA, Abou-Issa H and Seibert K. (2000). Cancer Res., 60, 2101-2103.
12. Howard J, Ung Y, Adachi D and Ben-David Y. (1996). Cell Growth Differ., 7, 1651-1660.
13. Howard JC, Li Q, Chu W, Zochodne B, Kapoor M, Ung Y, Rosen K and Ben-David Y. (2001). Oncogene, 20, 2291-2300.
14. Hwang D, Scollard D, Byrne J and Levine E. (1998). J. Natl. Cancer Inst., 90, 455-460.
15. Johnson P, Chung S and Benchimol S. (1993). Mol. Cell. Biol., 13, 1456-1463.
16. Li YJ, Higgins RR, Pak BJ, Shivdasani RA, Ney PA, Archer M and Ben-David Y. (2001). Mol. Cell. Biol., 21, 73-80.
17. Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R and Weinstein IB. (1999). Biochem. Pharmacol., 58, 1097-1107.
18. Lin MT, Lee RC, Yang PC, Ho FM and Kuo ML. (2001). J. Biol. Chem., 276, 48997-49002.
19. Mekori YA, Gilfillan AM, Akin C, Hartmann K and Metcalfe DD. (2001). J. Clin. Immunol., 21, 171-174.
20. Munroe DG, Peacock JW and Benchimol S. (1990). Mol. Cell. Biol., 10, 3307-3313.
21. Nakanishi Y, Kamijo R, Takizawa K, Hatori M and Nagumo M. (2001). Eur. J. Cancer, 37, 1570-1578.
22. Sachinidis A, Gouni-Berthold I, Seul C, Seewald S, Ko Y, Schmitz U and Vetter H. (1999). Br. J. Pharmacol., 128, 1761-1771.
23. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H and Monden M. (2000). Clin. Cancer Res., 61, 229-1238.
24. Shibuya T and Mak T. (1983). Proc. Natl. Acad. Sci., USA, 80, 3721-3725.
25. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A and Dannenberg AJ. (1999). J. Biol. Chem., 274, 10911-10915.
26. Tamir A, Howard J, Higgins RR, Li YJ, Berger L, Zacksenhaus E, Reis M and Ben-David Y. (1999). Mol Cell Biol., 19, 4452-4464.
27. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P and Discafani CM. (2000). Nat. Med., 6, 1024-1028.
28. Tsujii M and DuBois RN. (1995). Cell, 83, 493-501.
29. Tsujii M, Kuwano S and DuBois RN. (1997). Natl. Acad. Sci., USA, 94, 3336-3340.
30. Williams CS, Watson AJM, Sheng H, Helou R, Shao J and DuBois RN. (2000). Cancer Res., 60, 6045-6051.
31. Wong KS, Li YJ, Howard J and Ben-David Y. (1999). Oncogene, 18, 5525-5534.
32. Zhang L, Yu J, Park BH, Kinzler KW and Vogelstein B. (2000). Science, 90, 989-992.